Serum Squamous Cell Carcinoma-related Antigen Research Articles

Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: Comparison with SCC-Ag level

ObjectiveHigher level of circulating monocyte has been reported to be related with higher cancer incidence and mortality. We investigated the role of pre-treatment circulating monocyte count for cancer specific survival in cervical squamous cell carcinoma patients comparing with pre-treatment squamous cell carcinoma-related antigen (SCC-Ag) level. MethodsWe retrospectively enrolled patients with squamous cell carcinoma of the cervix (FIGO stage IB to IVA) who had complete blood cell counts with differential cell count and serum SCC-Ag level within 2weeks before starting initial treatment and were treated at Samsung Medical Center, Seoul, Korea, from 1996 to 2007. ResultsThe 788 patients in our study group had a median follow-up of 53.4months and a five-year survival rate of 87.8%. The median value for pre-treatment circulating monocyte count was 349/μl (21–1463), and the median concentration of SCC-Ag was 1.6ng/ml (0.1–362.0). In multivariable analysis, the pre-treatment circulating monocyte count was an independent prognostic factor for progression-free survival and overall survival in locally advanced disease (P=0.007 and P=0.038) but not in case of SCC-Ag for overall survival. The combined index of monocyte count and SCC-Ag level could enhance the prognostic value of SCC-Ag alone in patients with locally advanced cervical squamous cell carcinoma. ConclusionsA higher pre-treatment circulating monocyte count is independently associated with poor prognosis in patients with locally advanced cervical squamous cell carcinoma. The pre-treatment circulating monocyte count may be considered as an adjunctive biomarker with SCC-Ag.

Serum squamous cell carcinoma-related antigen in lung cancer--a marker for the extent of the disease and response to therapy

Serum squamous cell carcinoma-related antigen in lung cancer--a marker for the extent of the disease and response to therapy

Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels

We examined differences in the 2-year survival rate in bronchogenic squamous cell carcinoma patients with normal serum levels of both cytokeratin 19 fragment (CYFRA 21-1) and squamous cell carcinoma-related antigen (SCC) (NL group, n=15), patients with only increased SCC levels (SCC+ group, n=14), patients with only increased CYFRA 21-1 levels (CYFRA+ group, n=14), and patients with elevated levels of both CYFRA 21-1 and SCC (EL group, n=65). The 2-year survival rates for the CYFRA+ and the EL group were lower than those for the SCC+ group and the NL group (0 and 12.9% vs. 66.7 and 85.6%, log rank: p<0.0001, Wilcoxon: p<0.0001). However, there were no differences between the rate for the SCC+ and the NL group and between that for the CYFRA+ and the EL group. Serum carcinoembryonic antigen (CEA) levels increased in the patients with the elevated CYFRA 21-1 levels. This results suggest that there may be some differences between squamous cell carcinoma patients with increased CYFRA 21-1 levels and those with normal levels and that it is CYFRA 21-1 levels, not SCC levels, that relate to the prognosis.

口腔へん平上皮癌におけるＳＣＣ抗原およびＣＥＡの臨床的意義

Squamous cell carcinoma related antigen (SCC-Ag) and carcinoembryonic antigen (CEA) were respectively estimated by radioimmunoassay of serum samples obtained from 35 and 42 untreated patients with oral squamous cell carcinomas. The expression of SCC-Ag and CEA in the tumor tissue was also investigated immunohistochemically.Pathologic serum SCC-Ag levels in excess of the cut-off value (1.5 ng/ml) were observed in 37.1% of the patients. The serum SCC-Ag level correlated positively with clinical staging and tumor size according to the TNM classification and the degree of SCC-Ag expression on tumor cells, but did not correlate with the degree of differentiation, and the mode and stage of invasion. Furthermore, serial measurements of the serum SCC-Ag level revealed good and rapid responses to treatment. In contrast, elevated serum CEA levels over the cut-off value of 2.5 ng/ml were observed only in 11.9% of the patients. The serum CEA level did not show any correlation with clinical staging or other variables.Thus, the determination of serum SCC-Ag level was of clinical value in the pretherapeutic staging and post-therapeutic monitoring of disease, although it was not useful for the detection of early signs of disease. Compared with SCC-Ag, CEA was less useful as a tumor marker of oral squamous cell carcinomas.

High Level of Serum Squamous Cell Carcinoma-Related Antigen in a Case of Bowen’s Disease

A case of Bowen's disease on the lower abdomen is described. It was characterized by the unusually large size of the lesion and the high level of serum squamous cell carcinoma-related antigen which, however, decreased rapidly after surgical removal of the tumor.

血清ＳＣＣ抗原値に影響を与える因子について

The relationship between serum squamous cell carcinoma related antigen (SCC-Ag) level and pathohistological view and/or stainability of tissue SCC-Ag was examined in oral squamous cell carcinoma. The specimens taken from 97 patients were stained with a monoclonal antibody against the SCC-Ag by immunoperoxidase methods. The serum SCC-Ag level was measured by a radioimmunoassay system. The well-differentiated carcinomas were stained well with this antibody, whereas the poorly-differentiated cases were stained weakly or negatively. Serum SCC-Ag levels were significantly high in the cases of invasive carcinoma, but not in the well differentiation of the tumors cases and in the well stained cases. These observations suggested that the parenchymal-stromal relationship is decisive factors in determining the serum SCC-Ag level.

Significance of squamous cell carcinoma-related antigen in psoriasis and generalized eczema. Preliminary report.

The serum levels of squamous cell carcinoma-related antigen (SCC-RAG) were assayed in 15 cases of benign dermatoses. The SCC-RAG titers (2.0 ng/ml as the cutoff value) were elevated in all cases of wide-spreading psoriasis (7 cases, 2.4-96.1 ng/ml) and all cases of generalized eczema (3 cases, 11.2-33.6 ng/ml). The serum SCC-RAG levels correlated with clinical course of these dermatoses. Therefore, the increase in this cancer-related antigen is not specific for SCC but may also occur in a wide range of dermatoses.

Clinical assay of serum SCC-Ag in urothelial cancers.

Serum squamous cell carcinoma related antigen (SCC-Ag) values were determined in 86 patients with urothelial cancers. Mean +/- standard deviation for serum SCC-Ag, was 3.4 +/- 0.98 ng/ml and positive values (greater than 2.0 ng/ml) were found in 27%. Neither pathological stage nor cell grade of the urothelial cancer showed any relation to serum SCC-Ag. Serum SCC-Ag. changed parallel to the clinical course. These results suggest that, as there is no specific tumor marker in urothelial cancer, serum SCC-Ag. may be a useful aid in diagnosing cancer and monitoring these patients. Used together with another non-specific marker, an increase in the accuracy of diagnosis of these malignancies can be expected.